Calithera Biosciences Company Profile (NASDAQ:CALA)

About Calithera Biosciences (NASDAQ:CALA)

Calithera Biosciences logoCalithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. The Company's lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. CB-1158 is a potent and selective orally bioavailable inhibitor of the enzyme arginase. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. CB-1158 has single agent anti-tumor activity in syngeneic mouse tumor models that has been demonstrated to act through an immune mechanism. CB-1158 is being tested in a Phase I clinical trial in patients with solid tumors.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CALA
  • CUSIP: N/A
  • Web: www.calithera.com
Capitalization:
  • Market Cap: $561.17 million
  • Outstanding Shares: 35,294,000
Average Prices:
  • 50 Day Moving Avg: $12.53
  • 200 Day Moving Avg: $8.26
  • 52 Week Range: $2.20 - $17.40
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -15.44
  • P/E Growth: -0.22
Sales & Book Value:
  • Annual Revenue: $4.19 million
  • Price / Sales: 133.93
  • Book Value: $4.70 per share
  • Price / Book: 3.38
Profitability:
  • EBIDTA: ($33,840,000.00)
  • Return on Equity: -58.24%
  • Return on Assets: -54.26%
Debt:
  • Current Ratio: 12.21%
  • Quick Ratio: 12.21%
Misc:
  • Average Volume: 789,003 shs.
  • Beta: 3.18
  • Short Ratio: 2.16
 

Frequently Asked Questions for Calithera Biosciences (NASDAQ:CALA)

What is Calithera Biosciences' stock symbol?

Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."

How were Calithera Biosciences' earnings last quarter?

Calithera Biosciences Inc (NASDAQ:CALA) released its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.36) by $0.14. The company had revenue of $4.19 million for the quarter, compared to analysts' expectations of $1.40 million. View Calithera Biosciences' Earnings History.

Where is Calithera Biosciences' stock going? Where will Calithera Biosciences' stock price be in 2017?

4 brokers have issued 1 year target prices for Calithera Biosciences' stock. Their predictions range from $5.00 to $16.00. On average, they anticipate Calithera Biosciences' stock price to reach $11.75 in the next year. View Analyst Ratings for Calithera Biosciences.

What are analysts saying about Calithera Biosciences stock?

Here are some recent quotes from research analysts about Calithera Biosciences stock:

  • 1. According to Zacks Investment Research, "Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. It is focused on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The Company's lead product candidate includes CB-839 which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. Calithera Biosciences, Inc. is headquartered in South San Francisco, California. " (5/12/2017)
  • 2. JMP Securities analysts commented, "Calithera Biosciences reports achievement of PK and PD goals in the Phase I trial of CB-1158, which entitles the company to receive a $12MM milestone payment as per its collaboration agreement with Incyte (INCY, MO, PT UR, Bayko); reiterate our Market Outperform rating and $12 price target based on a synthesis of our DCF, SOTP, and comparable company valuation methodologies. We view this early milestone achievement as further validation of the company's collaboration with INCY as well as of the subject of the agreement, CB-1158, a first-in-class arginase inhibitor and potential immunotherapeutic. CB-1158 has thus far demonstrated favorable pharmacologic activity in human subjects, with elevated plasma arginine levels consistent with those seen in preclinical cancer models. We remind investors that additional clinical data for CB-1158 in the setting of immuno-oncology are expected in mid-2017." (3/28/2017)

Are investors shorting Calithera Biosciences?

Calithera Biosciences saw a drop in short interest during the month of April. As of April 28th, there was short interest totalling 743,060 shares, a drop of 52.8% from the April 13th total of 1,575,180 shares. Based on an average trading volume of 413,042 shares, the short-interest ratio is presently 1.8 days. Currently, 2.8% of the company's stock are sold short.

Who are some of Calithera Biosciences' key competitors?

Who owns Calithera Biosciences stock?

Calithera Biosciences' stock is owned by many different of institutional and retail investors. Top institutional investors include Wellington Management Group LLP (15.01%), FMR LLC (5.33%), Vanguard Group Inc. (3.37%), RA Capital Management LLC (2.05%), Bogle Investment Management L P DE (1.81%) and Monashee Investment Management LLC (1.20%). Company insiders that own Calithera Biosciences stock include Adage Capital Partners Gp Llc, Adage Capital Partners Gp, LL and Curtis Hecht. View Institutional Ownership Trends for Calithera Biosciences.

Who sold Calithera Biosciences stock? Who is selling Calithera Biosciences stock?

Calithera Biosciences' stock was sold by a variety of institutional investors in the last quarter, including Franklin Street Advisors Inc. NC and Oxford Asset Management. View Insider Buying and Selling for Calithera Biosciences.

Who bought Calithera Biosciences stock? Who is buying Calithera Biosciences stock?

Calithera Biosciences' stock was purchased by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, FMR LLC, RA Capital Management LLC, Bogle Investment Management L P DE, Vanguard Group Inc., Monashee Investment Management LLC, Candriam Luxembourg S.C.A. and Goldman Sachs Group Inc.. Company insiders that have bought Calithera Biosciences stock in the last two years include Adage Capital Partners Gp Llc and Adage Capital Partners Gp, LL. View Insider Buying and Selling for Calithera Biosciences.

How do I buy Calithera Biosciences stock?

Shares of Calithera Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Calithera Biosciences stock cost?

One share of Calithera Biosciences stock can currently be purchased for approximately $15.90.

Analyst Ratings

Consensus Ratings for Calithera Biosciences (NASDAQ:CALA) (?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $11.75 (26.10% downside)

Analysts' Ratings History for Calithera Biosciences (NASDAQ:CALA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/3/2017Leerink SwannReiterated RatingOutperform -> Outperform$16.00MediumView Rating Details
3/28/2017JMP SecuritiesReiterated RatingOutperform$12.00 -> $12.00MediumView Rating Details
3/28/2017HC WainwrightReiterated RatingBuy -> Buy$10.00 -> $14.00MediumView Rating Details
1/24/2017Citigroup IncUpgradeSell -> Neutral$5.00N/AView Rating Details
5/12/2016Wells Fargo & CoReiterated RatingBuyN/AView Rating Details
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$20.00 -> $12.00N/AView Rating Details
(Data available from 5/28/2015 forward)

Earnings

Earnings History for Calithera Biosciences (NASDAQ:CALA)
Earnings by Quarter for Calithera Biosciences (NASDAQ:CALA)
Earnings History by Quarter for Calithera Biosciences (NASDAQ:CALA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.36)($0.22)$1.40 million$4.19 millionViewListenView Earnings Details
3/16/2017Q4 2016($0.48)($0.45)ViewN/AView Earnings Details
11/9/2016Q3 2016($0.47)($0.44)ViewListenView Earnings Details
8/9/2016Q2($0.52)($0.55)ViewListenView Earnings Details
5/10/2016Q1($0.47)($0.52)ViewListenView Earnings Details
3/15/2016Q415($0.56)($0.44)ViewListenView Earnings Details
11/9/2015Q3($0.52)($0.49)ViewListenView Earnings Details
8/10/2015Q215($0.45)($0.44)ViewListenView Earnings Details
11/14/2014Q3 2014($0.28)($16.85)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Calithera Biosciences (NASDAQ:CALA)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.17)($0.17)($0.17)
Q3 20171($0.21)($0.21)($0.21)
Q4 20171($0.24)($0.24)($0.24)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Calithera Biosciences (NASDAQ:CALA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Calithera Biosciences (NASDAQ:CALA)
Insider Ownership Percentage: 27.50%
Institutional Ownership Percentage: 37.93%
Insider Trades by Quarter for Calithera Biosciences (NASDAQ:CALA)
Institutional Ownership by Quarter for Calithera Biosciences (NASDAQ:CALA)
Insider Trades by Quarter for Calithera Biosciences (NASDAQ:CALA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/19/2017Curtis HechtSVPSell650$16.00$10,400.00View SEC Filing  
3/22/2017Adage Capital Partners Gp, L.LMajor ShareholderBuy487,804$10.25$4,999,991.00View SEC Filing  
3/13/2017Curtis HechtSVPSell600$14.00$8,400.00View SEC Filing  
11/16/2016Adage Capital Partners Gp, L.LMajor ShareholderBuy500,000$3.15$1,575,000.00View SEC Filing  
11/16/2015Curtis HechtVPSell970$6.58$6,382.60View SEC Filing  
9/23/2015Adage Capital Partners Gp LlcMajor ShareholderBuy106,968$6.03$645,017.04View SEC Filing  
9/4/2015Adage Capital Partners Gp LlcMajor ShareholderBuy90,300$5.93$535,479.00View SEC Filing  
8/28/2015Adage Capital Partners Gp LlcMajor ShareholderBuy172,126$5.27$907,104.02View SEC Filing  
10/15/2014Adage Capital Partners Gp LlcMajor ShareholderBuy181,700$6.96$1,264,632.00View SEC Filing  
10/7/2014Jean GeorgeDirectorBuy300,000$10.00$3,000,000.00View SEC Filing  
10/7/2014Morgenthaler Venture PartnersMajor ShareholderBuy350,000$10.00$3,500,000.00View SEC Filing  
10/1/2014Adage Capital Partners Gp LlcMajor ShareholderBuy800,000$10.00$8,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Calithera Biosciences (NASDAQ:CALA)
Latest Headlines for Calithera Biosciences (NASDAQ:CALA)
Source:
DateHeadline
americanbankingnews.com logoCurtis Hecht Sells 650 Shares of Calithera Biosciences Inc (CALA) Stock
www.americanbankingnews.com - May 23 at 8:35 PM
finance.yahoo.com logo3 Under-the-radar Momentum Plays
finance.yahoo.com - May 22 at 12:47 PM
americanbankingnews.com logoCalithera Biosciences Inc (CALA) Short Interest Update
www.americanbankingnews.com - May 13 at 7:04 AM
americanbankingnews.com logoCalithera Biosciences Inc (CALA) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - May 12 at 4:40 PM
americanbankingnews.com logoCalithera Biosciences Inc to Post Q2 2017 Earnings of ($0.17) Per Share, Leerink Swann Forecasts (CALA)
www.americanbankingnews.com - May 12 at 10:40 AM
americanbankingnews.com logoCalithera Biosciences Inc (CALA) Releases Earnings Results, Beats Expectations By $0.14 EPS
www.americanbankingnews.com - May 10 at 10:58 PM
finance.yahoo.com logoEdited Transcript of CALA earnings conference call or presentation 9-May-17 8:30pm GMT
finance.yahoo.com - May 10 at 9:40 PM
streetinsider.com logoBristol-Myers (BMY), Calithera Biosciences (CALA) Expand Collaboration Evaluating Opdivo in Combination with CB ... - StreetInsider.com
www.streetinsider.com - May 10 at 8:34 AM
finance.yahoo.com logoBristol-Myers Squibb and Calithera Biosciences Expand Collaboration Evaluating Opdivo (nivolumab) in Combination with CB-839 into Non-Small Cell Lung Cancer and Melanoma
finance.yahoo.com - May 10 at 8:34 AM
nasdaq.com logoCalithera Biosciences Reports First Quarter 2017 Financial Results and Recent Highlights - Nasdaq
www.nasdaq.com - May 9 at 9:08 PM
marketbeat.com logoCalithera reports 1Q loss
marketbeat.com - May 9 at 5:21 PM
finance.yahoo.com logoInvestor Network: Calithera Biosciences, Inc. to Host Earnings Call
finance.yahoo.com - May 9 at 4:07 PM
finance.yahoo.com logoCalithera Biosciences to Report First Quarter 2017 Financial Results on Tuesday, May 9, 2017 - Yahoo Finance
finance.yahoo.com - May 4 at 9:18 PM
americanbankingnews.com logoCalithera Biosciences (CALA) Receives Daily News Impact Rating of 0.17
www.americanbankingnews.com - May 4 at 1:01 AM
americanbankingnews.com logoBrokerages Set Calithera Biosciences Inc (CALA) Price Target at $12.00
www.americanbankingnews.com - May 4 at 12:12 AM
finance.yahoo.com logoCalithera Biosciences to Report First Quarter 2017 Financial Results on Tuesday, May 9, 2017
finance.yahoo.com - May 3 at 8:07 AM
americanbankingnews.com logoCalithera Biosciences (CALA) Receiving Somewhat Positive Press Coverage, Study Finds
www.americanbankingnews.com - April 29 at 2:03 PM
americanbankingnews.com logoCalithera Biosciences Inc (CALA) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 28 at 12:00 PM
americanbankingnews.com logoCalithera Biosciences (CALA) Given News Sentiment Rating of 0.33
www.americanbankingnews.com - April 26 at 10:16 PM
americanbankingnews.com logoCalithera Biosciences (CALA) Getting Positive News Coverage, AlphaOne Reports
www.americanbankingnews.com - April 23 at 2:31 PM
finance.yahoo.com logoCB-1158 Phase I Data Accepted for an Oral Presentation at the ASCO Annual Meeting - Yahoo Finance
finance.yahoo.com - April 21 at 6:47 AM
americanbankingnews.com logoCalithera Biosciences (CALA) Given Daily Media Impact Rating of 0.41
www.americanbankingnews.com - April 20 at 4:05 PM
finance.yahoo.com logoCB-1158 Phase I Data Accepted for an Oral Presentation at the ASCO Annual Meeting
finance.yahoo.com - April 20 at 11:03 AM
americanbankingnews.com logoCalithera Biosciences (CALA) Receives Coverage Optimism Score of 0.28
www.americanbankingnews.com - April 14 at 9:14 AM
americanbankingnews.com logoCalithera Biosciences Inc (CALA) Short Interest Up 12.5% in March
www.americanbankingnews.com - April 7 at 8:31 PM
investopedia.com logoFirst Quarter Analysis: Winners and Losers in the Biotech Sector
www.investopedia.com - April 7 at 8:50 AM
americanbankingnews.com logoCalithera Biosciences Inc (CALA) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 6 at 4:45 PM
americanbankingnews.com logoEquities Analysts Offer Predictions for Calithera Biosciences Inc's Q2 2017 Earnings (CALA)
www.americanbankingnews.com - April 5 at 12:19 PM
americanbankingnews.com logoCalithera Biosciences Inc (CALA) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - April 5 at 10:22 AM
americanbankingnews.com logoLeerink Swann Reiterates "Outperform" Rating for Calithera Biosciences Inc (CALA)
www.americanbankingnews.com - April 3 at 1:17 PM
americanbankingnews.com logoCalithera Biosciences Inc (CALA) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 30 at 5:03 PM
finance.yahoo.com logoCalithera Biosciences to Present at the 16th Annual Needham Health Care Conference
finance.yahoo.com - March 29 at 12:31 PM
streetinsider.com logoCalithera Biosciences (CALA) to Receive $12M Milestone Payment From Incyte (INCY) - StreetInsider.com
www.streetinsider.com - March 28 at 8:56 PM
streetinsider.com logoCalithera Biosciences (CALA) to Receive $12M Milestone Payment From Incyte (INCY)
www.streetinsider.com - March 28 at 12:53 PM
americanbankingnews.com logoCalithera Biosciences Inc (CALA) Earns "Outperform" Rating from JMP Securities
www.americanbankingnews.com - March 28 at 12:26 PM
finance.yahoo.com logoCalithera Biosciences, Inc. Announces Closing of Public Offering and Exercise in Full of Option to Purchase Additional Shares
finance.yahoo.com - March 27 at 4:07 PM
americanbankingnews.com logoCalithera Biosciences Inc (CALA) Major Shareholder Adage Capital Partners Gp, L.L Buys 487,804 Shares
www.americanbankingnews.com - March 24 at 10:17 AM
finance.yahoo.com logoCALITHERA BIOSCIENCES, INC. Financials
finance.yahoo.com - March 23 at 4:32 PM
biz.yahoo.com logoCALITHERA BIOSCIENCES, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - March 22 at 3:52 PM
finance.yahoo.com logoCalithera Biosciences, Inc. Prices Public Offering of 6,830,000 shares of Common Stock
finance.yahoo.com - March 22 at 3:52 PM
streetinsider.com logoCalithera Biosciences (CALA) to Offer 4.5M Shares of Common Stock - StreetInsider.com
www.streetinsider.com - March 21 at 9:45 AM
rttnews.com logoCalithera Biosciences Inc. (CALA) Is Falling After Offering Announcement
www.rttnews.com - March 20 at 6:32 PM
finance.yahoo.com logo4:02 pm Calithera Biosciences commences 4.5 mln common stock offering
finance.yahoo.com - March 20 at 6:32 PM
finance.yahoo.com logoCalithera Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock
finance.yahoo.com - March 20 at 6:32 PM
finance.yahoo.com logoEdited Transcript of CALA earnings conference call or presentation 16-Mar-17 5:30pm GMT
finance.yahoo.com - March 17 at 4:45 PM
seekingalpha.com logoCalithera Biosciences' (CALA) CEO Susan Molineaux on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - March 16 at 10:26 PM
us.rd.yahoo.com logo4:08 pm Calithera Biosciences reports Q4 GAAP EPS of ($0.45), vs the ($0.48) Capital IQ Consensus Estimate
us.rd.yahoo.com - March 16 at 10:26 PM
nasdaq.com logoCalithera Biosciences Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Highlights - Nasdaq
www.nasdaq.com - March 16 at 5:24 PM
biz.yahoo.com logoQ4 2016 Calithera Biosciences Inc Earnings Release - Time Not Supplied
biz.yahoo.com - March 16 at 5:24 PM
finance.yahoo.com logoCalithera Biosciences Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Highlights
finance.yahoo.com - March 16 at 5:24 PM

Social

Chart

Calithera Biosciences (CALA) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff